Objective: Acute myeloid leukemia (AML) is primarily a malignant disorder affecting the elderly. We aimed to compare the outcomes of different treatment patterns in elderly AML patients and to propose a prognostic scoring system that could predict survival and aid therapeutic decisions.Methods: Patients aged ≥ 60 years who had been diagnosed with AML at 7 hospitals in China were enrolled (n = 228). Treatment patterns included standard chemotherapy, low intensity therapy, and best supportive care (BSC). Results: The early mortality rates were 31％, 6.8％, and 6.3％ for the BSC, low intensity therapy, and standard chemotherapy groups, respectively. The complete remission rate of the standard chemotherapy group was higher than that of the low intensity therapy group. The median overall survival (OS) was 561 days and 222 days for the standard chemotherapy and low intensity therapy groups, respectively, and were both longer than that of the BSC group (86 days). Based on multivariate analyses, we defined a prognostic scoring system that enabled classification of patients into 3 risk groups, in an attempt to predict the OS of patients receiving chemotherapies and low intensity therapies. Low and intermediate risk patients benefited more from standard chemotherapies than from low intensity therapies. However, the median OS was comparable between standard chemotherapies and low intensity therapies in high risk patients. Conclusions: Our prognostic scoring system could predict survival and help select appropriate therapies for elderly AML patients. Standard chemotherapy is important for elderly AML patients, particularly for those categorized into low and intermediate risk groups.

Chunli Zhang;Wei Wan;Shuai Zhang;Jingwen Wang;Ru Feng;Jiangtao Li;Junyue Chai;Hebing Zhou;Liru Wang;Yuping Zhong;Xiaodong Mo;Mengzhu Shen;Hongmei Jing;Hui Liu

Department of Hematology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Hematology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Department of Hematology,Beijing No.6 Hospital,Beijing 100007,China;Department of Hematology,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China;Department of Hematology,Fuxing Hospital,Capital Medical University,Beijing 100038,China;Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100043,China;Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China

癌症生物学与医学（英文版）

[1]Chunli Zhang;Wei Wan;Shuai Zhang;Jingwen Wang;Ru Feng;Jiangtao Li;Junyue Chai;Hebing Zhou;Liru Wang;Yuping Zhong;Xiaodong Mo;Mengzhu Shen;Hongmei Jing;Hui Liu-.Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China)[J].癌症生物学与医学（英文版）,2022(06):871-883

chemotherapies

Treatment,patterns,prognostic,scoring,system,elderly,acute,myeloid,leukemia,patients,retrospective,multicenter,cohort,study,China,Objective,Acute,AML,primarily,malignant,disorder,affecting,We,aimed,compare,outcomes,different,treatment,propose,that,could,predict,survival,aid,therapeutic,decisions,Methods,Patients,aged,years,who,had,been,diagnosed,hospitals,were,enrolled,included,standard,chemotherapy,low,intensity,best,supportive,care,BSC,Results,early,mortality,rates,groups,respectively,complete,remission,was,higher,than,median,overall,OS,days,both,longer,Based,multivariate,analyses,defined,enabled,classification,into,risk,attempt,receiving,Low,intermediate,benefited,more,from,However,comparable,between,Conclusions,Our,help,select,appropriate,Standard,important,particularly,those,categorized

0.453566